- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (66)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (28)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (228)
- Breast Cancer (712)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (154)
- Colon Cancer (164)
- Colorectal Cancer (110)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (6)
- Kidney Cancer (124)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (288)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (98)
- Ovarian Cancer (172)
- Pancreatic Cancer (166)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (234)
- Skin Cancer (294)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (30)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (622)
- Complementary Integrative Medicine (22)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (224)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (122)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (116)
- Molecular Diagnostics (8)
- Pain Management (64)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (880)
- Research (384)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (598)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (404)
- Survivorship (324)
- Symptoms (182)
- Treatment (1764)
AACR Honors Mendelsohn for 'Extraordinary Achievements'
2 minute read | Published March 28, 2012
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on March 28, 2012
The American Association for Cancer Research will present its sixth annual AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research to John Mendelsohn, M.D., at the association's annual meeting opening session this Sunday in Chicago.
Mendelsohn is co-director of MD Anderson's Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) and was president of MD Anderson from 1996 to 2011.
The award, announced today, recognizes a person who has had a major impact by conducting or supporting cancer research.
"Dr. Mendelsohn was a pioneer in the area of targeted cancer therapies, specifically working with EGFR tyrosine kinase inhibition," said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. "The AACR commends him for his groundbreaking research on targeted therapy, which opened the door to a new way of thinking about cancer and its treatment. In addition, Dr. Mendelsohn is both a nationally and internationally recognized leader in cancer policy."
The award is named for Foti, who has been chief executive officer of AACR, the world's oldest and largest cancer professional organization, since 1982. "I am thrilled to receive this award because it is in honor of a great leader, Dr. Foti, and because it recognizes my lifetime commitment to improving the care of cancer patients through research," Mendelsohn said. "I have been privileged to work with many outstanding laboratory and clinical investigators in initiating the field of targeted cancer therapy and in expanding translational cancer research programs at three great academic institutions."
The AACR announcement notes Mendelsohn's current leadership roles as chair of the National Cancer Policy Forum of the Institute of Medicine and as co-director of the IPCT, "a research program designed to embrace a multidisciplinary approach including laboratory researchers, clinicians and investigators to test cancer therapies targeting abnormal genes and gene products detected in an individual patient's cancer."
"Prior to this, Mendelsohn served as the president of MD Anderson from 1996 to 2011, recently stepping down to return to clinical and translational research. During his time as president, Mendelsohn worked with a visionary management team to transform the cancer center into what it is today, one of the world's most respected cancer research centers. Under his supervision and guidance, MD Anderson was ranked as number one in cancer care in the nation, for eight out of the last 10 years, in the "America's Best Hospitals" survey conducted by U.S. News & World Report."
Click here to read the entire AACR Foti Award announcement